Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 1,046.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,057.00 Cr. (Dec 2024) to 1,046.00 Cr., marking a decrease of 11.00 Cr..
For Expenses, as of Mar 2025, the value is 876.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,037.00 Cr. (Dec 2024) to 876.00 Cr., marking a decrease of 161.00 Cr..
For Operating Profit, as of Mar 2025, the value is 171.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Dec 2024) to 171.00 Cr., marking an increase of 151.00 Cr..
For OPM %, as of Mar 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 2.00% (Dec 2024) to 16.00%, marking an increase of 14.00%.
For Other Income, as of Mar 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Dec 2024) to 37.00 Cr., marking an increase of 5.00 Cr..
For Interest, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Dec 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
For Depreciation, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Dec 2024) to 34.00 Cr., marking an increase of 19.00 Cr..
For Profit before tax, as of Mar 2025, the value is 168.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Dec 2024) to 168.00 Cr., marking an increase of 134.00 Cr..
For Tax %, as of Mar 2025, the value is 15.00%. The value appears to be increasing, which may not be favorable. It has increased from -2.00% (Dec 2024) to 15.00%, marking an increase of 17.00%.
For Net Profit, as of Mar 2025, the value is 143.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Dec 2024) to 143.00 Cr., marking an increase of 109.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 31.89. The value appears strong and on an upward trend. It has increased from 7.61 (Dec 2024) to 31.89, marking an increase of 24.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:39 pm
Metric
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
3,188
3,660
2,769
2,803
2,710
3,167
3,609
4,261
4,734
5,140
5,103
5,473
Expenses
2,768
3,144
2,334
2,389
2,300
2,684
2,883
3,450
3,923
4,216
4,147
4,784
Operating Profit
419
516
435
414
410
483
726
812
812
924
956
690
OPM %
13%
14%
16%
15%
15%
15%
20%
19%
17%
18%
19%
13%
Other Income
91
88
82
70
39
51
-64
69
112
168
79
120
Interest
5
5
10
7
11
10
14
13
13
22
20
17
Depreciation
65
25
25
29
33
44
65
74
64
80
74
85
Profit before tax
441
574
482
448
404
480
583
794
847
990
941
707
Tax %
34%
33%
35%
35%
26%
30%
19%
38%
24%
23%
21%
20%
Net Profit
290
383
315
291
300
337
474
493
645
758
740
568
EPS in Rs
79.06
104.59
89.13
82.31
87.41
98.18
105.58
109.72
143.58
168.71
164.77
126.38
Dividend Payout %
7%
20%
19%
21%
21%
18%
24%
105%
104%
77%
85%
99%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
32.07%
-17.75%
-7.62%
3.09%
12.33%
40.65%
4.01%
30.83%
17.52%
-2.37%
-23.24%
Change in YoY Net Profit Growth (%)
0.00%
-49.82%
10.14%
10.71%
9.24%
28.32%
-36.64%
26.82%
-13.31%
-19.89%
-20.87%
Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
4%
5 Years:
9%
3 Years:
5%
TTM:
7%
Compounded Profit Growth
10 Years:
4%
5 Years:
0%
3 Years:
-2%
TTM:
-23%
Stock Price CAGR
10 Years:
4%
5 Years:
-1%
3 Years:
5%
1 Year:
-12%
Return on Equity
10 Years:
21%
5 Years:
23%
3 Years:
24%
Last Year:
20%
Last Updated: Unknown
No data available for the Balance Sheet data table.
After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
For Diluted EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
For Cash EPS (Rs.), as of Mar 25, the value is 145.41. This value is within the healthy range. It has decreased from 181.40 (Mar 24) to 145.41, marking a decrease of 35.99.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 140.00 (Mar 24) to 125.00, marking a decrease of 15.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,219.02. It has increased from 1,136.57 (Mar 24) to 1,219.02, marking an increase of 82.45.
For PBDIT / Share (Rs.), as of Mar 25, the value is 180.24. This value is within the healthy range. It has decreased from 230.51 (Mar 24) to 180.24, marking a decrease of 50.27.
For PBIT / Share (Rs.), as of Mar 25, the value is 161.34. This value is within the healthy range. It has decreased from 214.03 (Mar 24) to 161.34, marking a decrease of 52.69.
For PBT / Share (Rs.), as of Mar 25, the value is 157.55. This value is within the healthy range. It has decreased from 209.66 (Mar 24) to 157.55, marking a decrease of 52.11.
For Net Profit / Share (Rs.), as of Mar 25, the value is 126.50. This value is within the healthy range. It has decreased from 164.92 (Mar 24) to 126.50, marking a decrease of 38.42.
For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has decreased from 20.28 (Mar 24) to 14.78, marking a decrease of 5.50.
For PBIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 18.83 (Mar 24) to 13.23, marking a decrease of 5.60.
For PBT Margin (%), as of Mar 25, the value is 12.92. This value is within the healthy range. It has decreased from 18.44 (Mar 24) to 12.92, marking a decrease of 5.52.
For Net Profit Margin (%), as of Mar 25, the value is 10.37. This value exceeds the healthy maximum of 10. It has decreased from 14.51 (Mar 24) to 10.37, marking a decrease of 4.14.
For Return on Networth / Equity (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has decreased from 25.98 (Mar 24) to 19.92, marking a decrease of 6.06.
For Return on Capital Employeed (%), as of Mar 25, the value is 23.96. This value is within the healthy range. It has decreased from 32.03 (Mar 24) to 23.96, marking a decrease of 8.07.
For Return On Assets (%), as of Mar 25, the value is 10.82. This value is within the healthy range. It has decreased from 16.10 (Mar 24) to 10.82, marking a decrease of 5.28.
For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 1.10 (Mar 24) to 1.11, marking an increase of 0.01.
For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.44 (Mar 24) to 2.01, marking a decrease of 0.43.
For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.94, marking a decrease of 0.54.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.84. This value is below the healthy minimum of 4. It has increased from 1.48 (Mar 24) to 1.84, marking an increase of 0.36.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 81.93 (Mar 24) to 0.00, marking a decrease of 81.93.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 74.48 (Mar 24) to 0.00, marking a decrease of 74.48.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 18.07 (Mar 24) to 0.00, marking a decrease of 18.07.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 25.52 (Mar 24) to 0.00, marking a decrease of 25.52.
For Interest Coverage Ratio (X), as of Mar 25, the value is 47.61. This value is within the healthy range. It has decreased from 52.81 (Mar 24) to 47.61, marking a decrease of 5.20.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 34.41. This value is within the healthy range. It has decreased from 38.78 (Mar 24) to 34.41, marking a decrease of 4.37.
For Enterprise Value (Cr.), as of Mar 25, the value is 21,230.10. It has decreased from 22,377.29 (Mar 24) to 21,230.10, marking a decrease of 1,147.19.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.38 (Mar 24) to 3.88, marking a decrease of 0.50.
For EV / EBITDA (X), as of Mar 25, the value is 26.23. This value exceeds the healthy maximum of 15. It has increased from 21.62 (Mar 24) to 26.23, marking an increase of 4.61.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 18.06 (Mar 24) to 0.00, marking a decrease of 18.06.
For Price / BV (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has decreased from 8.26 (Mar 24) to 7.76, marking a decrease of 0.50.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Bayer CropScience Ltd as of June 26, 2025 is: 4,705.42
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, Bayer CropScience Ltd is Overvalued by 18.17% compared to the current share price 5,750.00
Intrinsic Value of Bayer CropScience Ltd as of June 26, 2025 is: 4,840.35
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, Bayer CropScience Ltd is Overvalued by 15.82% compared to the current share price 5,750.00
Last 5 Year EPS CAGR: 2.87%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 19.92% (Industry Average ROE: 19.94%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 45.5 (Industry average Stock P/E: 27.83)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Bayer Cropscience Ltd. is a Public Limited Listed company incorporated on 09/09/1958 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24210MH1958PLC011173 and registration number is 011173. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company's Total Operating Revenue is Rs. 5473.40 Cr. and Equity Capital is Rs. 44.90 Cr. for the Year ended 31/03/2025.
INDUSTRY
ADDRESS
CONTACT
Agro Chemicals/Pesticides
Bayer House, Central Avenue, Mumbai Maharashtra 400607
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bayer CropScience Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
